TARGETED CELLULAR CYTOTOXICITY

靶向细胞毒性

• 批准号: 3813455
• 负责人: D M SEGAL
• 金额: --
• 依托单位: DIVISION OF CANCER BIOLOGY AND DIAGNOSIS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3813455
• 关键词: CD3 molecule; T cell receptor; antibody dependent killer cell; antibody receptor; antigen presentation; antigen presenting cell; antireceptor antibody; antitumor antibody; athymic mouse; cell mediated cytotoxicity; cross immunity; crosslink; cytolysis; cytotoxic T lymphocyte; human tissue; immunoconjugates; interleukin 2; leukocyte activation /transformation; major histocompatibility complex; neoplasm /cancer immunology; ovary neoplasms

1. Bispecific antibodies with specificity for TcR gamma/delta chains can induce human PBL subsets to lyse surrogate target cells. Not all targetable activity is in the gamma/delta + T cells. 2. Targeted human PBL exhibited an anti-tumor activity mediated by factors secreted into the medium. This activity leads to the eradication of bystander tumor cells, and appears to operate both in vitro and in vivo. 3. Targeted human PBL can block intraperitoneal growth of established human ovarian carcinoma in nude mice. The potency of the effect is donor dependent, and varies with the type of bispecific antibody used, the mode of activation of the PBL, and the treatment schedule.

1.对TcR γ/δ链具有特异性的双特异性抗体可以 诱导人PBL亚群裂解替代靶细胞。并非所有目标 活性存在于γ/δ + T细胞中。 2.靶向的人PBL具有抗肿瘤活性， 分泌到培养基中。这项活动导致根除 旁观者肿瘤细胞，并且似乎在体外和体内都起作用。 3.靶向人PBL可以阻断已建立的人PBL的腹膜内生长， 裸鼠卵巢癌。效应的效力是供体 依赖性，并且随所用双特异性抗体的类型而变化， PBL的激活和治疗方案。